DVAX Stock: Dynavax Technologies Reaches $15.35 After 9.00% Down Move

0
206

The stock of Dynavax Technologies Corporation (NASDAQ:DVAX) is a huge mover today! The stock decreased 4.36% or $0.7 during the last trading session, reaching $15.35. About 1.07 million shares traded. Dynavax Technologies Corporation (NASDAQ:DVAX) has declined 63.84% since January 12, 2017 and is downtrending. It has underperformed by 80.54% the S&P500.The move comes after 5 months negative chart setup for the $930.15 million company. It was reported on Jan, 12 by Barchart.com. We have $13.97 PT which if reached, will make NASDAQ:DVAX worth $83.71 million less.

The stock decreased 0.07% or $0.01 during the last trading session, reaching $13.95. About 18,962 shares traded. Nuveen Select Tax-Free Income Portfolio 2 (NXQ) has declined 3.77% since January 12, 2017 and is downtrending. It has underperformed by 20.47% the S&P500.

Among 6 analysts covering Dynavax Technologies (NASDAQ:DVAX), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Dynavax Technologies had 19 analyst reports since August 12, 2015 according to SRatingsIntel. The stock of Dynavax Technologies Corporation (NASDAQ:DVAX) has “Neutral” rating given on Wednesday, April 27 by JP Morgan. The firm earned “Buy” rating on Monday, July 31 by William Blair. The stock of Dynavax Technologies Corporation (NASDAQ:DVAX) earned “Buy” rating by RBC Capital Markets on Friday, September 1. The stock of Dynavax Technologies Corporation (NASDAQ:DVAX) has “Hold” rating given on Friday, July 21 by J.P. Morgan. RBC Capital Markets maintained the shares of DVAX in report on Monday, September 25 with “Buy” rating. The firm has “Buy” rating by William Blair given on Monday, August 7. RBC Capital Markets upgraded Dynavax Technologies Corporation (NASDAQ:DVAX) on Monday, July 31 to “Outperform” rating. The rating was maintained by William Blair with “Buy” on Friday, July 21. RBC Capital Markets maintained it with “Buy” rating and $28.0 target in Sunday, October 29 report. On Wednesday, September 27 the stock rating was maintained by Cantor Fitzgerald with “Buy”.

Investors sentiment decreased to 2.06 in Q3 2017. Its down 0.27, from 2.33 in 2017Q2. It worsened, as 13 investors sold Dynavax Technologies Corporation shares while 19 reduced holdings. 25 funds opened positions while 41 raised stakes. 41.91 million shares or 20.83% more from 34.68 million shares in 2017Q2 were reported. Eam Ltd Liability holds 0.68% or 237,938 shares. Nationwide Fund Advsrs holds 0.01% or 101,247 shares in its portfolio. Howard Hughes Institute holds 0.11% or 21,355 shares in its portfolio. California-based Franklin Inc has invested 0.01% in Dynavax Technologies Corporation (NASDAQ:DVAX). Credit Suisse Ag holds 0% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX) for 214,428 shares. Morgan Stanley invested 0% in Dynavax Technologies Corporation (NASDAQ:DVAX). Ny State Common Retirement Fund holds 0% in Dynavax Technologies Corporation (NASDAQ:DVAX) or 52,400 shares. Blackrock stated it has 3.85M shares. 200,000 are held by Weiss Multi. American Int Group reported 0% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX). D E Shaw And has invested 0.07% in Dynavax Technologies Corporation (NASDAQ:DVAX). Schwab Charles has 235,310 shares. Mufg Americas has invested 0% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX). Tower Cap Ltd Company (Trc) invested in 3,187 shares. Citigroup Inc holds 712,120 shares or 0.01% of its portfolio.

Analysts await Dynavax Technologies Corporation (NASDAQ:DVAX) to report earnings on March, 12. They expect $-0.35 earnings per share, up 37.50% or $0.21 from last year’s $-0.56 per share. After $-0.38 actual earnings per share reported by Dynavax Technologies Corporation for the previous quarter, Wall Street now forecasts -7.89% EPS growth.

Dynavax Technologies Corporation, a clinical-stage immunotherapy company, focuses on leveraging the power of the bodyÂ’s innate and adaptive immune responses through toll-like receptor stimulation. The company has market cap of $930.15 million. The Company’s product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. It currently has negative earnings. The companyÂ’s lead product candidates include HEPLISAV-B, an investigational adult hepatitis B vaccine, which is in Phase III clinical trials; and SD-101, an investigational cancer immunotherapeutic that is in Phase I/II studies.

Since December 13, 2017, it had 0 insider buys, and 2 selling transactions for $199,261 activity. $141,750 worth of stock was sold by COFFMAN ROBERT on Wednesday, December 13. $57,511 worth of Dynavax Technologies Corporation (NASDAQ:DVAX) shares were sold by Johnson David Louis.

Tortoise Investment Management Llc holds 1.14% of its portfolio in Nuveen Select Tax-Free Income Portfolio 2 for 266,252 shares. Financial & Investment Management Group Ltd owns 48,000 shares or 0.22% of their US portfolio. Moreover, Koshinski Asset Management Inc. has 0.11% invested in the company for 23,250 shares. The Florida-based Thomas J. Herzfeld Advisors Inc. has invested 0.07% in the stock. 1607 Capital Partners Llc, a Virginia-based fund reported 56,100 shares.

LEAVE A REPLY

Please enter your comment!
Please enter your name here